Drug intelligence / Profile preview

NW-7-255

Development stage: Preclinical
Lead developer: Newave Pharmaceutical
Modality: Small Molecules

Overview

NW-7-255 is a preclinical diagnostic agent developed by Newave Pharmaceutical. It is designed as a mutation-specific probe targeting the BTK-F107C/C variant of Bruton's tyrosine kinase (BTK). The agent is intended for use in the context of hematological malignancies, potentially serving as a companion diagnostic or imaging agent to identify patients harboring specific BTK mutations. Such mutations can influence treatment response or confer resistance to standard BTK inhibitor therapies, making their detection critical for personalized treatment strategies in B-cell malignancies.

Targets

BTK (Bruton tyrosine kinase)

Beyond the preview

Go deeper on NW-7-255.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NW-7-255.

Explore the full profile